Alterations of immunologic mediators during severe sepsis

ISRCTN ISRCTN34508816
DOI https://doi.org/10.1186/ISRCTN34508816
ClinicalTrials.gov number NCT00484146
Secondary identifying numbers LAVISS_01
Submission date
20/04/2006
Registration date
13/06/2006
Last edited
01/02/2019
Recruitment status
Stopped
Overall study status
Stopped
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Armin Sablotzki
Scientific

Delitzscher Str. 141
Leipzig
04129
Germany

Phone +49 (0)341 909 2570
Email armin.sablotzki@sanktgeorg.de

Study information

Study designProspective, open, clinical observational study
Primary study designObservational
Secondary study designCohort study
Study setting(s)Hospital
Study typeScreening
Scientific titleAlterations of immunologic mediators during severe sepsis
Study objectivesSevere sepsis induces significant changes in expression of insulin and toll-like receptors, cytokines, markers of apoptosis, and activation of t- and b-lymphocytes.
Ethics approval(s)Ethics approval received from the Ethics Committee of the Saxonian Chamber of Physicians on the 21st July 2006 (ref: EK-BR-15/06-1).
Health condition(s) or problem(s) studiedSevere sepsis
InterventionDaily blood samples for 7 days
Intervention typeOther
Primary outcome measureAlterations of immunologic parameters
Secondary outcome measuresNot provided at time of registration
Overall study start date01/06/2006
Completion date31/12/2007
Reason abandoned (if study stopped)Participant recruitment issue

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants40
Key inclusion criteria1. Age 18 years or older
2. Agreement with study procedures, informed consent
3. Fulfilling 3 out of 4 criteria of a systemic inflammatory response syndrome (SIRS)
4. Suspected or proven infection
5. Two or more sepsis-induced organ dysfunctions
6. Start of first sepsis-induced organ dysfunction within the last 36 hours
Key exclusion criteria1. Non-agreement with study procedures
2. Sign of severe sepsis for more than 36 hours
3. Chronic immuno-compromizing diseases
4. Chronic therapy with anti-inflammatory drugs
5. Non-curable cancer diseases
6. Chronic renal failure with hemodialysis
7. Pregnant or breast feeding
Date of first enrolment01/06/2006
Date of final enrolment31/12/2007

Locations

Countries of recruitment

  • Germany

Study participating centre

Delitzscher Str. 141
Leipzig
04129
Germany

Sponsor information

Urban Clinical Center of St Georg in Leipzig (Städt. Klinikum St. Georg, Leipzig) (Germany)
Hospital/treatment centre

Delitzscher Str. 141
Leipzig
04129
Germany

Phone +49 (0)341 909 2570
Email kais@sanktgeorg.de
Website http://www.sanktgeorg.de
ROR logo "ROR" https://ror.org/02y8hn179

Funders

Funder type

Hospital/treatment centre

Urban Clinical Center of St Georg in Leipzig (Städt. Klinikum St. Georg Leipzig) (Germany)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Editorial Notes

01/02/2019: Clinicaltrials.gov states that this trial was terminated by October 2012 due to low accrual